-
International Journal of Women's Health
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Gender-related mortality for HIV-infected patients on highly active antiretroviral therapy (HAART) in rural Uganda
Original Research
(1800) Views (634) Full article downloads
Authors: Arif Alibhai, Walter Kipp, L Duncan Saunders, et al
Published Date April 2010
Volume 2010:2 Pages 45 - 52
DOI: http://dx.doi.org/10.2147/IJWH.S9408
Arif Alibhai1, Walter Kipp1, L Duncan Saunders1, Ambikaipakan Senthilselvan1, Amy Kaler2, Stan Houston3, Joseph Konde-Lule4, Joa Okech-Ojony5, Tom Rubaale5
1Department of Public Health Sciences, 2Department of Sociology, 3Department of Medicine, University of Alberta, Edmonton, Canada; 4School of Public Health, Makerere University, Kampala, Uganda; 5Kabarole Health Department, Fort Portal, Uganda
Abstract: The purpose of this study was to examine gender differences in mortality for human immunodeficiency virus (HIV) patients in rural Western Uganda after six months of highly active antiretroviral therapy (HAART). Three hundred eighty five patients were followed up for six months after initiating HAART. Statistical analysis included descriptive, univariate and multivariate methods, using Kaplan–Meier estimates of survival distribution and Cox proportional hazards regression. Mortality in female patients (9.0%) was lower than mortality in males (13.5%), with the difference being almost statistically significant (adjusted hazard ratio for females 0.55; 95% confidence interval [CI]: 0.28–1.07; P = 0.08). At baseline, female patients had a significantly higher CD4+ cell count than male patients (median 147 cells/μL vs 120 cells/μL; P < 0.01). A higher CD4+ cell count and primary level education were strongly associated with better survival. The higher CD4+ cell count in females may indicate that they accessed HAART services at an earlier stage of their disease progression than males. A borderline statistically significant lower mortality rate in females shows that females fare better on treatment in this context than males. The association between lower mortality and higher CD4+ levels suggest that males are not accessing treatment early enough and that more concerted efforts need to be made by HAART programs to reach male HIV patients.
Keywords: antiretroviral treatment, gender, rural, Uganda
Readers of this article also read:
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Health literacy and health seeking behavior among older men in a middle-income nation
Enucleation following treatment with intravenous pentamidine for Acanthamoeba sclerokeratitis
Erratum
Editorial
Erratum
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Erratum
- Interested in being a peer-reviewer?
Click here to register.
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- Contraceptive practices in Nigeria: Literature review and recommendation for future policy decisions
- Tinidazole in the treatment of bacterial vaginosis
- Diagnosis and management of pre-eclampsia: an update
- Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy




